Articles tagged with Prostate Cancer
Researchers will study the biology of tumor-stroma interaction, heparan sulfate proteoglycans in bone metastasis, and mitochondrial DNA mutations to develop novel diagnostic and therapeutic strategies. The goal is to understand how prostate cancer cells metastasize to bone and discover new genes that may support or inhibit this process.
Research studies reveal that weight loss, exercise, and dietary changes can lower breast cancer risk by up to five percent of body weight and increase physical activity levels associated with reduced mammographic breast density. Additionally, a low-carbohydrate diet may be more effective in preventing prostate cancer progression.
Researchers found correlations between cellular features and cancer development in prostate and ovarian cancers. Prostatic intraepithelial neoplasia may be a significant target for prevention strategies.
Scientists at Memorial Sloan-Kettering Cancer Center discovered that the amount of PTEN protein produced affects prostate cancer progression. Mouse models showed varying levels of PTEN protein led to aggressive or benign tumors, suggesting novel clinical strategies for diagnosis, treatment, and prevention.
Researchers created mouse models to study PTEN's impact on prostate cancer progression. Subtle reductions in PTEN dose produced progressive changes in the biology of tumors, with mice having no functional PTEN genes showing the most invasive and aggressive cancers.
A study by Pollack and colleagues finds that a high Ki-67 biomarker is linked to increased risk of distant metastasis and death in prostate cancer patients. The researchers also suggest that Ki-67 can help identify high-risk patients who may benefit from alternative treatment strategies.
High doses of radiation therapy directed at the prostate significantly impact cancer control in high-risk patients. The major site of treatment failure is the prostate, highlighting the importance of high doses in this group.
Researchers discovered a genetic link between prostate cancer and a specific gene variant, CYPIBI. The study found that tiny variations in the gene may increase or decrease its cancer-causing effects, leading to a higher risk of developing prostate cancer.
Researchers at Penn aim to understand factors influencing poor prostate cancer outcomes among African-American men, including biological, environmental, and behavioral aspects. The study's findings may help develop better tools for prevention and treatment, ultimately improving clinical outcomes for this underserved population.
A recent study found that men aged 55-74 who received regular prostate cancer screenings every 4 years had a low rate of interval cancers. The screening procedure showed an 85.5% high sensitivity rate for detecting cancers, suggesting that very few aggressive prostate cancers escape screening.
Researchers have created a new method that could detect diseases at earlier stages than possible now, using protein targets like PSA. The method is a million times more sensitive than conventional methods and has the potential to revolutionize cancer diagnostics and treatment.
Prostate cancer mortality rates are falling fast in the US and Europe due to earlier diagnosis and hormonal treatments. Research shows that prompt surgery and hormonal therapy can improve 10-year survival rates for both prostate and breast cancers.
A systematic review and meta-analysis found that men with a family history of prostate cancer have an increased risk of developing the disease. The study revealed a 2.9 fold increased risk when the affected relative was a brother, highlighting the importance of identifying at-risk populations for targeted screening.
A clinical trial found that oral sodium clodronate reduced the risk of symptomatic bone progression by 21% and mortality by 20% compared to placebo, but with limited statistically significant results due to small population size. However, side effects were common, particularly in older patients.
A new nomogram model predicts prostate cancer likelihood in men with PSA levels below 10 ng/ml, helping to reduce unnecessary biopsies. The model identifies four independent risk factors for positive biopsy results and provides a score to calculate the likelihood of cancer presence.
Research identifies three SNPs in PSA gene promoter that increase serum PSA levels, suggesting genotyping may improve prostate cancer detection sensitivity. The findings suggest a lower cutoff value for PSA testing for men with reduced PSA promoter genotype.
A new study identified three genetic variants associated with a 30% increase in prostate-specific antigen (PSA) levels. The discovery could lead to more accurate testing and fewer unnecessary biopsies, particularly for black men who are at higher risk of developing prostate cancer.
Long-term, heavy smoking significantly increases prostate cancer risk in middle-aged men, with double the risk of aggressive forms. Current smokers also face a 40% higher risk compared to nonsmokers.
A new test using ProPSA detected prostate cancer at lower PSA levels, identifying more aggressive forms of the disease. The test improved detection of early aggressive cancer in men who may not have been caught until it was too late.
Researchers found that high zinc intake was associated with an increased risk of advanced prostate cancer, but not with lower doses. The studies also failed to find evidence of simian virus 40 (SV40) DNA in non-Hodgkin's lymphoma samples.
Researchers have identified a genetic marker, MSR1, that increases prostate cancer risk in African-American men. The study, which recruited over 400 black men from Flint, Mich., found that rare germ-line mutations were associated with an increased risk.
A new study by UT Southwestern finds that finasteride effectively reduces prostate cancer risk and improves symptoms in men with benign prostatic hyperplasia. The drug, already used to treat BPH, works by inhibiting the conversion of testosterone to dihydrotestosterone, which is involved in prostate cancer development.
Finasteride has been shown to prevent prostate cancer in both low-risk and high-risk men. However, those on finasteride were more likely to develop high-grade cancers.
The study showed that FDHT-PET detected osseous lesions in patients with advanced metastatic prostate cancer, confirming its utility in evaluating prostate cancer patients. The test also revealed the presence of additional lymph node lesions not identified by CT scans, suggesting its potential to predict response to hormone therapy.
FDHT PET detected 46 lesions, outperforming conventional methods, which identified 59. The agent rapidly absorbed in metastatic lesions indicating functioning androgen receptors. Notably, FDHT uptake reduced in patients starting testosterone therapy.
A new experimental imaging technique has been developed to detect prostate cancer metastases in abdominal lymph nodes. The technique uses advanced high-resolution MR imaging, computerized image analysis, and a novel contrast agent to identify malignant nodes with high accuracy.
Researchers found that increasing RKIP expression in metastatic prostate cancer cells decreased their invasiveness and reduced lung metastases in mice. The study suggests that RKIP may be a suppressor of prostate cancer metastasis, offering new targets for cancer control.
A study suggests that extending screening intervals could reduce lead-time bias and overdetection rates associated with prostate cancer screenings. The research estimates a potential 60-90% increase in prostate cancer incidence, highlighting the need to weigh benefits against risks.
Researchers discovered that a lost protein called PEDF can inhibit angiogenesis, a crucial process for tumor growth, in prostate cancer cells. Treatment with PEDF also triggered increased cell death in cancer cells, suggesting its potential as a new treatment option.
A study of over 78,000 women found that those who worked rotating night shifts for years had a 35% greater risk of developing colorectal cancer. Additionally, research on melanoma suggests two separate pathways may lead to its development, and polymorphisms in certain genes may be associated with prostate cancer risk.
Researchers at M. D. Anderson Cancer Center found that combining Gleevec with chemotherapy resulted in significant drops in PSA levels in some patients, indicating potential therapeutic benefit. The combination therapy showed slow but sustained responses, suggesting a valid target in prostate cancer treatment.
A recent study found that whey protein increased glutathione levels in human prostate cells by up to 64%, potentially protecting against prostate cancer. Whey contains the amino acid cysteine, essential for producing glutathione, which helps control free radicals.
Researchers found that nearly half of men with elevated PSA levels had returned to normal levels after a year or more, making unnecessary biopsies possible. Repeating the PSA test after waiting at least six weeks may reduce unnecessary procedures and small incidental tumors.
Researchers discovered that 3,3'-diindolylmethane (DIM) inhibits the proliferation of human prostate cancer cells by acting as a powerful anti-androgen. DIM, found in cruciferous vegetables like broccoli, decreases PSA levels and blocks the effects of androgen on cancer cells.
Researchers identified a strong association between EZH2 and ECAD biomarkers and prostate cancer recurrence. Moderate or strong expression of EZH2 coupled with at most moderate expression of ECAD is most strongly associated with biochemical recurrence.
A UC Davis study found that a soy extract supplement reduced PSA levels in men with untreated prostate cancer. The study involved 62 men who received genistein concentrated polysaccharide for six months, resulting in an average decrease of 17% in PSA levels.
Blocking the activation of Stat5 in prostate cancer cells triggers extensive cell death, providing a new targeted therapeutic approach to manage cancer growth and metastasis. Prostate cancer is the second leading cause of cancer death in men, with approximately 220,900 new cases expected in the US in 2003.
Researchers have discovered that injecting herpes simplex virus vectors can deliver neurotrophic factors to damaged nerves, improving intracavernous pressure in rats. This concept could translate to humans, enabling gene therapy as a prophylactic treatment for men undergoing radical prostatectomy.
A multi-center study analyzing 2,056 prostate cancer patients found that metastatic disease carries a significant mortality rate and incurs substantial healthcare expenses. Patients with metastatic disease had ten times the death rate of those with localized disease, with $13,650 more in annual healthcare costs.
Researchers discovered that specific p53 mutations facilitate androgen-independent growth in human prostate cells, while another gene, Id-1, promotes tumor aggressiveness. These findings could lead to new therapeutic strategies for hormone-independent prostate cancer.
A new technique developed by Malins' laboratory uses Fourier transform-infrared spectroscopy to analyze DNA from prostate tumor biopsies, allowing doctors to identify patients at high risk for metastasis. This breakthrough enables more informed treatment decisions and potentially saves lives.
Researchers identified lifestyle factors that predict prostate cancer recurrence in treated patients. Patients with low body mass index, regular exercise, and annual screenings had lower risk of progression.
Researchers found that 11C-acetate PET scans were more sensitive than 18F-FDG PET scans in detecting recurrent prostate cancer. The study used 46 patients with detectable serum PSA, and the imaging procedures were conducted on the same day.
Researchers discovered a link between genetic markers and prostate cancer spread in African-American men. The study found that the ratio of MMP to E-cadherin accurately predicted cancer metastasis.
A $10 million grant will fund a new prostate cancer research consortium led by Emory University, comprising 13 universities from eight states. The consortium aims to identify new therapeutic targets for advanced prostate cancer treatment.
A new study by Dartmouth researchers finds that more American men are screened for prostate cancer than for colorectal cancer, contradicting scientific evidence. The study, which analyzed data from over 50,000 men, reveals a significant disparity in screening rates between the two cancers.
A study found that 75% of men aged 50 and older reported undergoing PSA testing, compared to 63% for colorectal cancer screening. The mismatch between screening rates highlights the need for better patient education on effective cancer tests.
A new study led by Queen's University aims to increase the sensitivity of prostate cancers to anti-cancer drugs using nitroglycerine. Researchers hope to develop a better understanding of how prostate cancer cells become resistant to chemotherapy, with potential applications for other cancers such as breast cancer.
The Prostate Cancer Series assesses the epidemiology of prostate cancer, highlighting the impact of genetic and environmental risk factors. Despite progress in understanding diet-related risks, familial clustering, and ethnic variation remain poorly understood, presenting opportunities for further research.
A Mayo Clinic phase II study of 42 patients with advanced androgen-independent prostate cancer found that green tea did not provide therapeutic benefit. The study showed no sustained decline in PSA levels, and high doses of green tea were associated with significant side effects.
A study by Dr. Michael Gaziano and colleagues found a significant link between greater height and increased risk of prostate cancer in men aged 50 and above, with risks increasing by 32% for those over 72 inches tall. However, no association was found between weight or body mass index and prostate cancer risk.
Researchers found the prevalence of overweight among Los Angeles County school children to be 20.6 percent, with higher rates among boys and Latinos. An email-based program for nutrition intervention was also shown to be effective in changing dietary behavior, with over 50% of participants reporting success.
Researchers found that selenium supplements reduced DNA damage in elderly male dogs' prostates, potentially benefiting aging prostate health. A separate study suggests a new retinoid treatment may prevent lung cancer in former smokers by restoring RAR-ß expression and reducing squamous metaplasia.
A recent study found that over 75% of participants took supplements regularly, with women using more supplements overall and men with medical conditions taking more supplements. The study suggests that healthcare providers need to educate patients on safe supplement use to prevent potential harm.
Researchers have found a promising combination therapy that may significantly improve treatment outcomes for patients with advanced prostate cancer. In a phase II clinical trial, the combination of calcitriol and docetaxel showed a higher PSA response rate compared to docetaxel alone.
Researchers found that a flaxseed-rich diet inhibited tumor growth and reduced aggression in genetically engineered mice. The study suggests that lignans in flaxseed could play a role in inhibiting prostate cancer progression by influencing estrogen and testosterone metabolism.
Researchers found that PC-SPES reduced the effectiveness of paclitaxel treatment in both androgen-sensitive and androgen-independent models of prostate carcinoma. Consumption of garlic, chives, and other allium vegetables may be associated with a reduced risk of prostate cancer.
The UCLA SPORE will focus on identifying new molecular targets for therapies and investigating nutritional strategies to prevent prostate cancer. Researchers will work together to develop targeted therapies that focus on what is broken in the cancer cell.
A new blood test has been developed to detect prostate cancer with high accuracy, helping identify men who need a biopsy and those who don't. The test correctly identified 36 of 38 prostate cancer cases, as well as 70 asymptomatic men with benign conditions.
Researchers have developed a test that analyzes protein patterns in blood serum samples to predict prostate cancer diagnosis. The technique proved effective in identifying 95% of cases and 78% of benign diseases, showing promise as a new tool for reducing unnecessary biopsies.